VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
+0.15%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$474M
AUM Growth
+$427M
(+909%)
Cap. Flow
+$429M
Cap. Flow
% of AUM
90.37%
Top 10 Holdings %
Top 10 Hldgs %
10.55%
Holding
454
New
296
Increased
64
Reduced
55
Closed
20
Top Buys
| 1 |
OXLC
Oxford Lane Capital
OXLC
|
$6.67M |
| 2 |
Barings BDC
BBDC
|
$6.25M |
| 3 |
Oxford Square Capital
OXSQ
|
$5.46M |
| 4 |
ECC
Eagle Point Credit Co
ECC
|
$5.43M |
| 5 |
FS KKR Capital
FSK
|
$5.08M |
Top Sells
Sector Composition
| 1 | Financials | 23.58% |
| 2 | Real Estate | 14.99% |
| 3 | Energy | 13.55% |
| 4 | Healthcare | 12.23% |
| 5 | Materials | 8.21% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
MDCO
176
DELISTED
Medicines Co
MDCO
| $837K | 0.18% |
+22,945
| New | +$837K |
|
177
Biogen
BIIB
$20.6B
| $832K | 0.18% |
3,556
+1,180
| +50% | +$276K |
|
178
Regeneron Pharmaceuticals
REGN
$60.8B
| $830K | 0.18% |
2,652
+581
| +28% | +$182K |
|
179
Theravance Biopharma
TBPH
$703M
| $829K | 0.17% |
50,751
+22,139
| +77% | +$362K |
|
|
SGEN
180
DELISTED
Seagen Inc. Common Stock
SGEN
| $818K | 0.17% |
+11,817
| New | +$818K |
|
181
Neurocrine Biosciences
NBIX
$14.3B
| $814K | 0.17% |
9,646
-1,025
| -10% | -$86.5K |
|
|
ICPT
182
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $810K | 0.17% |
10,180
+3,042
| +43% | +$242K |
|
183
United Therapeutics
UTHR
$18.1B
| $808K | 0.17% |
10,348
+3,264
| +46% | +$255K |
|
184
Puma Biotechnology
PBYI
$253M
| $803K | 0.17% |
63,142
+29,764
| +89% | +$379K |
|
185
Enanta Pharmaceuticals
ENTA
$189M
| $796K | 0.17% |
9,433
-1,201
| -11% | -$101K |
|
186
Omeros
OMER
$284M
| $784K | 0.17% |
+49,968
| New | +$784K |
|
187
Vanda Pharmaceuticals
VNDA
$272M
| $781K | 0.16% |
+55,444
| New | +$781K |
|
|
CELG
188
DELISTED
Celgene Corp
CELG
| $775K | 0.16% |
+8,388
| New | +$775K |
|
189
Franklin FTSE India ETF
FLIN
$2.31B
| $676K | 0.14% |
29,077
+586
| +2% | +$13.6K |
|
|
GTHX
190
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $440K | 0.09% |
14,360
+5,706
| +66% | +$175K |
|
|
PGNX
191
DELISTED
Progenics Pharmaceuticals Inc
PGNX
| $402K | 0.08% |
+65,214
| New | +$402K |
|
192
Krystal Biotech
KRYS
$4.35B
| $395K | 0.08% |
+9,800
| New | +$395K |
|
|
RARX
193
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
| $377K | 0.08% |
12,543
-3,645
| -23% | -$110K |
|
|
ARQL
194
DELISTED
Arqule Inc
ARQL
| $358K | 0.08% |
+32,522
| New | +$358K |
|
195
MeiraGTx Holdings
MGTX
$619M
| $349K | 0.07% |
+12,997
| New | +$349K |
|
196
Xencor
XNCR
$610M
| $348K | 0.07% |
8,514
+1,354
| +19% | +$55.3K |
|
197
Iovance Biotherapeutics
IOVA
$901M
| $342K | 0.07% |
+13,962
| New | +$342K |
|
|
TECX
198
Tectonic Therapeutic, Inc. Common Stock
TECX
$314M
| $320K | 0.07% |
1,641
+737
| +82% | +$144K |
|
199
Apellis Pharmaceuticals
APLS
$3.55B
| $319K | 0.07% |
12,600
-1,738
| -12% | -$44K |
|
200
TG Therapeutics
TGTX
$5.11B
| $318K | 0.07% |
36,741
-17,202
| -32% | -$149K |
|